Skip to main content

Table 1 Immunoexpression of HER-2/neu and p53 in relation to clinicopathological parameters of breast carcinoma

From: Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients

Parameters Total number
of patients
No. %
HER-2
overexpression
P53
immunoexpression
   Positive
No. %
Negative
No. %
Positive
No. %
Negative
No. %
Type of breast tissue      
Normal 20 (17.39) 0 (0) 20 (100) 0 (0) 20 (100)
Benign (fibroadenoma) 25 (21.74) 0 (0) 25 (100) 0 (0) 25 (100)
Malignant 70 (60.87) 33 (47.14) 37 (52.86) 25 (35.71) 45 (64.29)
  P < 0.05    P < 0.05  
Histological type      
Lobular carcinomas 8 (11.43) 1 (12.50) 7 (87.50) 2 (25) 6 (75)
Ductal carcinomas including: 62 (88.57) 32 (51.61) 30 (48.39) 23 (37.10) 39 (62.90)
  P < 0.05    P > 0.05  
Pure IDC 47 (67.14) 19 (40.43) 28 (59.57) 18 (38.30) 29 (61.70)
IDC + DCIS 9 (12.86) 7 (77.68) 2 (22.22) 2 (22.22) 7 (77.78)
IDC+ Paget's 2 (2.86) 2 (100) 0 (0) 1 (50) 1 (50)
DCIS + Paget's 1 (1.44) 1 (100) 0 (0) 1 (100) 0 (0)
Pure DCIS 3 (4.29) 3 (100) 0 (0) 1 (33.33) 2 (66.67)
  P < 0.05    P > 0.05  
Tumor grade      
Well-moderately differentiated (I and II) 14 (20) 7 (50) 7 (50) 2 (14.29) 12 (85.71)
Poorly differentiated (III) 56 (80) 26 (46.43) 30 (53.57) 23 (41.07) 33 (58.93)
  P > 0.05, R > 0.3    P > 0.05, R > 0.3
Tumor size      
Tis 4 (5.71) 4 (100) 0 (0) 2 (50) 2 (50)
T1 (≤
2 cm)
7 (10) 2 (28.57) 5 (71.43) 2 (28.57) 5 (71.43)
T2 (2 > -5 cm) 38 (54.29) 13 (34.21) 25 (65.79) 6 (15.79) 32 (84.21)
T3 (> 5 cm) 19 (27.14) 13 (68.42) 6 (31.58) 14 (73.68) 5 (26.32)
T4 (anyT+other) 2 (2.86) 1 (50) 1 (50) 1 (50) 1 (50)
  P < 0.05 R < 0.3   P < 0.05 R > 0.3
Axillary lymph nodes1      
Negative 27 (48.21) 6 (22.22) 2 (77.78) 7 (25.93) 20 (74.07)
Positive 29 (51.79) 19 (65.52) 10 (34.48) 17 (58.62) 12 (41.38)
  P < 0.05    P < 0.05  
Age of the patient      
< 35 years 19 (27.14) 12 (63.16) 7 (36.84) 8 (42.11) 11 (57.89)
> 35years 51 (72.86) 21 (41.18) 30 (58.82) 17 (33.33) 34 (66.67)
  P > 0.05    P > 0.05  
Tumor recurrence      
Primary 51 (72.86) 17 (33.33) 34 (66.67) 13 (25.49) 38 (74.51)
Recurrent 19 (27.14) 16 (84.21) 3 (15.79) 12 (63.16) 7 (36.84)
  P < 0.05    P < 0.05